One month degarelix/comparator treatment for prostate cancer in Chinese population
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
285
Cumulative probability of testosterone at castrate level (≤0.5 ng/mL)
Time frame: Day 28 to Day 364
Proportion of patients with testosterone levels ≤0.5 ng/mL
Time frame: at Day 3
Percentage change in prostate-specific antigen (PSA)
Time frame: from baseline to Day 28
Changes in testosterone and PSA levels
Time frame: Day 0 to 364
Significant changes in laboratory values
Time frame: Day 0 to Day 364
Significant changes in vital signs
Time frame: Day 0 to Day 364
Significant changes in body weight
Time frame: Day 0 to Day 364
Frequency and severity of adverse events
Time frame: Day 0 to Day 364
Cumulative probability of no PSA failure
PSA failure defined as two consecutive (at least two weeks apart) increase of 50 percentage and at least 5ng/mL increase compared to nadir
Time frame: Day 0 to Day 364
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army
Chongqing, Chongqing Municipality, China
1st Afilliated Hospital of Guangzhou Medical College
Guangzhou, Guangdong, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine
Xi’an, Shanxi, China
1st Hospital Affiliated to Zhejiang University Medical School
Hangzhou, Zhejiang, China
Beijing Hospital of Ministry of Health
Beijing, China
Peking Union Hospital
Beijing, China
Peking University 3rd Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
...and 19 more locations